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Abstract
Background: Lowering the diagnostic threshold for troponin is controversial because it may disproportionately increase the diagnosis of myocardial infarction in patients without acute coronary syndrome. We assessed the impact of lowering the diagnostic threshold of troponin on the incidence, management and outcome of patients with type 2 myocardial infarction or myocardial injury.
Methods: Consecutive patients with elevated plasma troponin I concentrations (≥50 ng/L; n=2,929) were classified as type 1 (50%) myocardial infarction, type 2 myocardial infarction or myocardial injury (48%) and type 3-5 myocardial infarction (2%) before and after lowering the diagnostic threshold from 200 to 50 ng/L with a sensitive assay. Event-free survival from death and recurrent myocardial infarction was recorded at one year.
Results: Lowering the threshold increased the diagnosis of type 2 myocardial infarction or myocardial injury more than type 1 myocardial infarction (672 versus 257 additional patients, P<0.001). Patients with myocardial injury or type 2 myocardial infarction were at higher risk of death compared to type 1 myocardial infarction (37% versus 16%; RR 2.31, 95%CI 1.98-2.69), but had fewer recurrent myocardial infarctions (4% versus 12%; RR 0.35, 0.26-0.49).
In patients with troponin concentrations 50-199 ng/L, lowering the diagnostic threshold was associated with increased healthcare resource utilization (P<0.05) that reduced recurrent myocardial infarction and death for patients with type 1 myocardial infarction (31% versus 20%; RR 0.64, 0.41-0.99), but not type 2 myocardial infarction or myocardial injury (36% versus 33%; RR 0.93, 0.75-1.15).
Conclusion:
Following implementation of a sensitive troponin assay, the incidence of type 2 myocardial infarction or myocardial injury disproportionately increased and is now as frequent as type 1 myocardial infarction. Outcomes of patients with type 2 myocardial infarction or myocardial injury are poor and do not appear to be modifiable following reclassification despite substantial increases in healthcare resource utilization.
Introduction
The Universal Definition of Myocardial Infarction proposes a classification for patients with myocardial infarction based on etiology in order to accommodate more sensitive markers of myocardial necrosis. 1 The classification differentiates between type 1 myocardial infarction, due to thrombosis of an atherosclerotic plaque, and type 2 myocardial infarction due to an imbalance of myocardial blood supply and demand that may arise in many acute medical and surgical conditions. The expert consensus further defines evidence of myocardial necrosis in the absence of clinical evidence of myocardial ischemia as myocardial injury. Whilst this classification has been used in recent clinical trials to refine clinical outcomes [2] [3] [4] , type 2 myocardial infarction and myocardial injury are difficult to distinguish or diagnose definitively, and the frequency in clinical practice and implications of these diagnoses are uncertain. 5, 6 Following improvements in assay performance, a sensitive troponin assay was introduced into our institution. 7, 8 The validation and subsequent implementation of this assay provided an opportunity to assess the impact of lowering the diagnostic threshold on the incidence, management and clinical outcome of patients with type 2 myocardial infarction and myocardial injury.
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Methods
Study population
We identified consecutive patients admitted to our regional cardiac center (Royal Infirmary, Edinburgh, United Kingdom), with plasma cardiac troponin I concentrations ≥50 ng/L irrespective of clinical presentation during the validation and implementation of a contemporary sensitive troponin assay. We report a pre-specified analysis from a published cohort study evaluating the impact of implementation of a contemporary sensitive troponin assay on patients with suspected acute coronary syndrome. 7 In this analysis we include all patients in whom troponin was measured as part of routine clinical care whether or not they presented with suspected acute coronary syndrome.
Clinical characteristics as described previously 7 including the primary presenting symptom, referral to specialist cardiology services, cardiac investigations, percutaneous or surgical coronary revascularization and the use of medical therapies were obtained through 'TrakCare'
(InterSystems Corporation, Cambridge, MA, USA): an electronic patient record system used by all hospitals in National Health Service (NHS) Lothian, United Kingdom. Exclusion criteria included patients admitted for elective non-emergency procedures, patients resident outwith Lothian, and those incomplete hospital records.
Troponin assay
Plasma troponin I concentrations were measured using the ARCHITECT STAT assays (Abbott Laboratories, Abbott Park, IL). The study was divided into two phases: validation and implementation. Whilst plasma troponin was measured using the reformulated sensitive assay throughout both phases, only concentrations above our previous diagnostic threshold (≥200
ng/L) were reported in the validation phase, whilst concentrations above the revised diagnostic threshold (≥50 ng/L) were reported during the implementation phase.
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Classification of myocardial infarction
Patients were classified as having a type 1 myocardial infarction when myocardial necrosis occurred in the context of an isolated presentation with suspected acute coronary syndrome with chest pain or evidence of myocardial ischemia on the electrocardiogram. 1 Patients with symptoms and signs of myocardial ischemia on the electrocardiogram which were thought to be due to either increased oxygen demand or decreased supply (e.g. tachyarrhythmia, hypotension or anemia) and myocardial necrosis, were classified as having a type 2 myocardial infarction. Myocardial injury was defined as evidence of myocardial necrosis in the absence of any clinical features of myocardial ischemia. Myocardial infarction presenting as a sudden unexpected cardiac death (type 3), following percutaneous coronary intervention (type 4) and coronary artery bypass grafting (type 5) were also defined. Each case was reviewed and classified independently by two cardiologists and any discrepancies resolved by consensus through indepth review of source data. Four hundred consecutive patients were classified by two internal medicine physicians to determine the generalisability of classification.
Outcomes
Clinical outcomes were identified using national and local population registries, the General
Register of Scotland and TrakCare respectively. The primary outcomes were recurrent type 1 myocardial infarction and all-cause mortality at one year. Recurrent myocardial infarction was defined as admission with chest pain or ST-segment deviation of ≥0.5 mm with evidence of myocardial necrosis using plasma troponin concentrations of ≥50 ng/L as the diagnostic
threshold. Secondary outcomes were coronary revascularization, stroke, gastrointestinal bleeding 9 and length of stay.
Statistical Analysis
Summary clincial statistics were compared by type of myocardial infarction, and between implementation and validation phases using Chi-squared, Fisher's exact, Students t-and Mann-Whitney U tests where appropriate. Agreement for the classification of myocardial infarction was estimated using Cohen's kappa. Cox regression models were used to explore competing risks. Cause specific hazard ratios were estimated for type 1 versus 2 myocardial infarction and myocardial injury for time to death and time to recurrent myocardial infarction seperately with adjustment for age and sex. Analyses were performed in SPSS (IBM Version 20.0.0, USA) and R (Version 2.14.2, Austria). patients with myocardial injury: a 22%, 56% and 64% increase respectively (P<0.001). The incidence rate for type 1, type 2 myocardial infarction, and myocardial injury increased with age ( Figure 1 ).
Clinical characteristics
Compared to type 1 myocardial infarction, patients with type 2 myocardial infarction or myocardial injury were older, had worse renal function and were more likely to be female ( 
Management during index admission
Compared to type 1 myocardial infarction, patients with type 2 myocardial infarction or myocardial injury were less likely to be referred to cardiology services, undergo in-patient coronary angiography and revascularization, and discharged on secondary preventative therapies (P<0.01 for all; Table 2 Table 2 ).
In patients with troponin concentration of 50-199 ng/L and type 1 myocardial infarction, lowering the diagnostic threshold increased the number of patients referred for a specialist opinion, further investigations and treatments for myocardial infarction (P<0.01 for all; Figure   2 and eTable 1). Lowering the diagnostic threshold also increased the number of patients with type 2 myocardial infarction or myocardial injury referred to the cardiologists for further
investigation, although the proportion of patients referred was less than for type 1 myocardial infarction, and the use of therapies for myocardial infarction was unchanged.
Clinical outcomes
Compared to patients with type 1 myocardial infarction, patients with type 2 myocardial infarction were more likely to die (16% versus 37%, RR 1 
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Discussion
considerable overlap between how these two clinical entities. 5, 6 The consensus document does not provide specific criteria on how to differentiate between these entities in clinical practice and our analysis represents one of the first attempts to do so in consecutive hospitalised patients. Thus, our frequency data may differ from those of others who may have applied a different criteria to define type 1 myocardial infarction and may or may not have had a category for myocardial injury. Accordingly, the frequency of type 2 myocardial infarction in our study of 20% (429/2,165) was lower than the only previous reports where the frequency was 30% (64/701 patients) 17 and 26% (144/553 patients) 18 in unselected hospitalised patients with elevated troponin concentrations. Our analysis is novel in that we distinguish between patients with type 2 myocardial infarction and myocardial injury, and differences in classification may explain the lower rates of type 2 myocardial infarction in our cohort.
Perhaps unsurprisingly, type 2 myocardial infarction has been reported to be less frequent (2 to 5%) in highly selected populations with myocardial infarction from randomised controlled trials or registries of patients admitted to cardiac units. 4, 19, 20 Our patients were widely distributed across medical and surgical specialties, and it is likely selection bias has underestimated the prevelance of type 2 myocardial infarction in these studies.
One of the main strengths of our study is that we identified a group of patients admitted during the validation period in whom plasma troponin concentrations of 50-199 ng/L were reported as normal. This allowed us to assess the impact of implementation of a sensitive troponin assay on the management and clinical outcome of these patients. Lowering the diagnostic threshold for myocardial infarction increased the use of appropriate investigations and treatments in patients with type 1 myocardial infarction. This was associated with a reduction in recurrent myocardial infarction and death consistent with our previous report. with type 2 myocardial infarction compared to type 1 myocardial infarction. 21 Importantly, despite more patients being identified as having type 2 myocardial infarction after lowering the diagnostic threshold, the majority of these patients did not receive additional therapies for coronary heart disease. This may represent a missed opportunity to improve outcomes and further prospective studies are required to define the optimal management of patients with type 2 myocardial infarction.
The increased frequency of type 2 myocardial infarction or myocardial injury is likely to be even more marked with the development of the next generation high-sensitivity troponin assays that will permit further lowering of the diagnostic threshold for myocardial infarction. [22] [23] [24] These assays are likely to identify an even greater and more disproportionate number of patients with myocardial injury or type 2 myocardial infarction. However, this must not detract from the substantial benefits that high-sensitivity assays will confer for diagnosing patients with type 1 myocardial infarction. 25, 26 This underlines the need to provide additional guidance on how to distinguish between myocardial infarction and myocardial injury.
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We believe there remains scope for clarification of the diagnostic criteria for type 2 myocardial infarction and that this is necessary to help clinicians adopt the proposed classification. Acute myocardial injury should be the initial diagnosis in all patients with troponin elevations due to supply-demand imbalance including those with chest pain or M A N U S C R I P T
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13 evidence of myocardial ischemia. This would be in keeping with many other organ systems, such as acute liver or kidney injury, where similar elevations in tissue enzymes or biomarkers confer major prognostic value, but are not disease specific. In our opinion, type 2 myocardial infarction should be used exclusively in patients where coronary artery disease has contributed to myocardial injury and where there may be opportunities to improve outcomes through medical therapy or coronary revascularization. Selection of patients for further investigation will depend on the mechanism of myocardial injury and the patient's probability of having coronary artery disease. Despite our careful attempts to classify patients, we were reliant on investigations performed by attending clinicians. Whilst agreement between our adjudicating cardiologists and internal medicine physicians was excellent, we accept that a small proportion of patients with type 2 myocardial infarction or myocardial injury may have been misclassified. Furthemore, we were unable to differentiate between acute and chronic myocardial injury in many patients as serial samples were requested at the discretion of the clinical team and were not routinely obtained in patients without suspected acute coronary syndrome.
In conclusion, we have demonstrated that type 2 myocardial infarction and myocardial injury are now as common as type 1 myocardial infarction in clinical practice. Using a sensitive troponin assay, we identified three patients with type 2 myocardial infarction or myocardial injury for every patient reclassified as type 1 myocardial infarction. Whilst this was associated with better treatment and outcomes in patients with type 1 myocardial infarction, patients with type 2 myocardial infarction or myocardial injury underwent more investigations and utilized additional cardiac services without altering their poor clinical outcome. The incidence rate was estimated as the number of events during the total 12-month period divided by the mid-year population estimates for that age-specific stratum. 10 Patients <75
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years had a higher incidence of type 1 than type 2 myocardial infarction or myocardial injury (124 versus 60 per 100,000 persons) whereas the reverse was true for patients ≥75 years (750 versus 1,008 per 100,000 persons). 
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In patients with troponin concentrations of 50-199 ng/L and type 1 myocardial infarction, lowering the diagnostic threshold increased referrals for a specialist opinion, further investigation and treatments for myocardial infarction (P<0.01 for all). For patients with type 2 myocardial infarction and myocardial injury similar patterns were seen although the absolute magnitude was smaller. In patients with type 1 myocardial infarction, lowering the diagnostic threshold was associated with a significant reduction in recurrent myocardial infarction (absolute risk reduction 12%, 95% CI 3 to 23%) whereas outcomes in patients with type 2 myocardial infarction and myocardial injury remained unchanged. PCI = percutaneous coronary intervention; DAPT = dual anti-platelet therapy. *P<0.05, ** P<0.01, ***P<0.001 M A N U S C R I P T 
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